NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a clinical stage biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage, and infection, will be presenting at this year's The MicroCap Conference on April 4th in New York City, sponsored by The Special Equities Group and Maxim Group. David C. Cavalier, Chairman and Chief Financial Officer, will be giving the presentation and meeting with investors.

Mr. Cavalier will provide an update on Aeolus' development pipeline, including its $118.4 million advanced R & D contract with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the U.S. Department of Health and Human Services. The BARDA contract funds the advanced development of AEOL 10150 ("10150") for the treatment of the pulmonary and delayed effects of acute radiation exposure ("Lung-ARS") following a nuclear detonation or accident. 10150 has demonstrated efficacy in multiple mouse and non-human primate Lung-ARS studies, and is being developed under the FDA Animal Rule, which allows the use of animal studies in indications where human efficacy trials are not possible. 10150 is also being developed for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") and for use in oncology to reduce the side effects of radiation therapy for solid tumors. The Company is also developing AEOL 11114 as a treatment for Parkinson's disease with support from the Michael J. Fox Foundation for Parkinson's disease. A third compound, AEOL 20415, is in development for the treatment of infectious diseases.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers - only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click "Register."

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

• The Special Equities Group

• Maxim Group

PARTICIPATING SPONSORS

• MZ Group

• Core IR

• Marcum

• PCG Advisory Group

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com.

SOURCE: Aeolus Pharmaceuticals, Inc.